Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690330 | 0.82 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1753418 | 0.81 | PTGDR2 (0.76) | PTGDR2RORC | |
| SCHEMBL2111491 | 0.77 | PTGDR2 (0.70) | PTGDR2 | |
| SCHEMBL2110294 | 0.76 | PTGDR2 (0.62) | PTGDR2RORC | |
| SCHEMBL1753656 | 0.72 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL11178796 | 0.72 | TDP1 (0.53) | — | |
| SCHEMBL29472205 | 0.72 | TDP1 (0.53) | — | |
| SCHEMBL1690281 | 0.71 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL12147066 | 0.70 | PTGDR2 (0.85) | PTGDR2 | |
| SCHEMBL12147356 | 0.70 | PTGDR2 (0.83) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611091-B1 | Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment | ASTRAZENECA AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | PTGDR2 438/4885RORC 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.